
TELA Stock Forecast & Price Target
TELA Analyst Ratings
Bulls say
TELA Bio is a commercial-stage medical technology company that has recently announced Q4'25 results, which missed top-line estimates but showed improvements on the operating loss side. The company's lowered outlook for 2026 growth is attributed to its own overhaul of its commercial team and go-to-market strategy, but the recent additions of experienced MedTech executives and a solid unit volume growth are positive indicators for future business momentum. The company's capital raise and up-sized debt capacity also provide financial flexibility for its planned expansion and execution. However, consistent execution and stable sales force are crucial for TELA to regain investor confidence and demonstrate its long-term ability to capture market share and generate operational leverage.
Bears say
TELA Bio is facing significant headwinds in the commercialization and sales of its soft-tissue reconstruction solutions, which has led to a significant cut in its sales growth outlook for 2026. Despite a strong product portfolio and growing demand for robotic and laparoscopic procedures, the company's sales team reorganization and high turnover rate among sales representatives have impacted its ability to generate revenue and meet its targets. Additionally, the company's concentrated product portfolio and reliance on reimbursement for healthcare procedures pose significant risks to its future growth and financial stability. With a negative outlook on the company's top-line performance, we believe that TELA Bio's stock is overvalued and are recommending a sell rating for investors.
This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
TELA Analyst Forecast & Price Prediction
Start investing in TELA
Order type
Buy in
Order amount
Est. shares
0 shares